ALBUQUERQUE, N.M., Oct. 14, 2020 /PRNewswire/ — Innovative solar technology company, mPower Technology, today announced that its DragonSCALES™ solar cell prototype has completed integration and testing on a Sparkwing in-orbit solar array technology demonstrator in preparation for inclusion on Momentus’ Vigoride transfer vehicle launch taking place in the fourth quarter of 2020.
DragonSCALES was developed to provide a low-cost, voltage-adjustable, high packing factor and lightweight solar power module that streamlines panel assembly and is designed for the needs of commercial LEO (low earth orbit) satellite constellations.
The Sparkwing team has introduced a groundbreaking new approach towards low cost, fast-delivery solar arrays for smallsats by offering a catalogue approach for standardized solar array models, similar to the automotive industry. The team is interested in mPower’s solar cell technology because of its potential to offer a unique combination of cost and performance benefits for next-gen solar arrays.
When immune system T cells find and recognise a target, they release chemicals to attract more T cells which then swarm to help subdue the threat, shows a new study published today in eLife.
The discovery of this swarming behaviour, and the chemical attractants that immune cells use to direct swarms towards tumours, could one day help scientists develop new cancer therapies that boost the immune system. This is particularly important for solid tumours, which so far have been less responsive to current immunotherapies than cancers affecting blood cells.
“Scientists have previously thought that cancer-killing T cells identified tumours by randomly searching for them or by following the chemical trails laid by other intermediary immune cells,” says lead author Jorge Luis Galeano Niño, a PhD graduate at UNSW Sydney. “We wanted to investigate this further to see if it’s true, or whether T cells locate tumours via another mechanism.”
Scientists have created an unprecedented 3-dimensional structural model of a key molecular “machine” known as the BAF complex, which modifies DNA architecture and is frequently mutated in cancer and some other diseases. The researchers, led by Cigall Kadoch, PhD, of Dana-Farber Cancer Institute, have reported the first 3-D structural “picture” of BAF complexes purified directly from human cells in their native states — rather than artificially synthesized in the laboratory -providing an opportunity to spatially map thousands of cancer-associated mutations to specific locations within the complex.
“A 3-D structural model, or ‘picture,’ of how this complex actually looks inside the nucleus of our cells has remained elusive — until now,” says Kadoch. The newly obtained model represents “the most complete picture of the human BAF complex achieved to date,” said the investigators, reporting in the journal Cell.
These new findings “provide a critical foundation for understanding human disease-associated mutations
Sequencing RNA from individual cells can reveal a great deal of information about what those cells are doing in the body. MIT researchers have now greatly boosted the amount of information gleaned from each of those cells, by modifying the commonly used Seq-Well technique.
With their new approach, the MIT team could extract 10 times as much information from each cell in a sample. This increase should enable scientists to learn much more about the genes that are expressed in each cell, and help them to discover subtle but critical differences between healthy and dysfunctional cells.
“It’s become clear that these technologies have transformative potential for understanding complex biological systems. If we look across a range of different datasets, we can really understand the landscape of health and disease, and that can give us information as to what therapeutic strategies we might employ,” says Alex K. Shalek, an associate professor
A team led by scientists in the Perelman School of Medicine at the University of Pennsylvania has engineered powerful new antimicrobial molecules from toxic proteins found in wasp venom. The team hopes to develop the molecules into new bacteria-killing drugs, an important advancement considering increasing numbers of antibiotic-resistant bacteria which can cause illness such as sepsis and tuberculosis.
In the study, published today in the Proceedings of the National Academy of Sciences, the researchers altered a highly toxic small protein from a common Asian wasp species, Vespula lewisii, the Korean yellow-jacket wasp. The alterations enhanced the molecule’s ability to kill bacterial cells while greatly reducing its ability to harm human cells. In animal models, the scientists showed that this family of new antimicrobial molecules made with these alterations could protect mice from otherwise lethal bacterial infections.
There is an urgent need for new drug treatments for bacterial infections, as
In biological terms, gliding refers to the type of movement during which a cell moves along a surface without changing its shape. This form of movement is unique to parasites from the phylum Apicomplexa, such as Plasmodium and Toxoplasma. Both parasites, which are transmitted by mosquitoes and cats, have an enormous impact on global heath. Plasmodium causes 228 million malaria infections and around 400,000 deaths per year. Toxoplasma, which infects even one third of the human population, can cause severe symptoms in some people, and is particularly dangerous during pregnancy.
Gliding enables the Apicomplexa parasites to enter and move between host cells. For example, upon entering the human body through a mosquito bite, Plasmodium glides through human skin before crossing into human blood vessels. This type of motion relies on actin and myosin, which are the same proteins that enable muscle movement in humans and other vertebrates. Myosin has a
Osaka, Japan — The current COVID-19 climate has made vaccines, antibodies, and immune responses topics of everyday conversation. Now, it isn’t just immunologists who want to know how our bodies respond to re-infections months, years, or sometimes decades after an initial immune response. A new study by Tomohiro Kurosaki at Osaka University shows that this ability requires Bach2, a protein that regulates the expression of genes needed to instruct activated B cells under selection to become memory B cells.
Like most biological processes, immune responses are complicated. They involve numerous types of cells and proteins, performing precise step-by-step processes. And of course, we don’t know all of them yet. For example, memory B cells are a type of white blood cell that are created in lymph nodes or spleens during an infection. They stick around for years and allow
Tesla may be planning to build batteries at its forthcoming Texas factory.
In documents filed to the state’s Commission on Environmental Quality, the company mentions a proposal for cell production.
Last month, CEO Elon Musk said Tesla found new innovations to bring down the cost of producing batteries while integrating them inside of its cars more efficiently.
Visit Business Insider’s homepage for more stories.
Tesla may be planning to build battery cells alongside Cybertrucks and other vehicles at its newest factory, set to open in 2021.
Documents filed with the state’s Commission on Environmental Quality, first reported by the Austin Business Journal, cite battery cell manufacturing among activities to occur at the 2,100-acre site near Austin.
“The facility is proposing to operate a cell-manufacturing unit to produce the battery packs that are installed in the vehicle,” one of the permit applications first spotted by Bloomberg says.
The CRISPR/Cas9 gene-editing tool is one of the most promising approaches to advancing treatments of genetic diseases – including cancer -, an area of research where progress is constantly being made.
Now, the Molecular Cytogenetics Unit led by Sandra Rodríguez-Perales at the Spanish National Cancer Research Centre (CNIO) has taken a step forward by effectively applying this technology to eliminate so-called fusion genes, which in the future could open the door to the development of cancer therapies that specifically destroy tumors without affecting healthy cells. The paper is published in Nature Communications.
Fusion genes are the abnormal result of an incorrect joining of DNA fragments that come from two different genes, an event that occurs by accident during the process of cell division. If the cell cannot benefit from this error, it will die and the fusion genes will be eliminated.
Recent work led by Carnegie’s Kamena Kostova revealed a new quality control system in the protein production assembly line with possible implications for understanding neurogenerative disease.
The DNA that comprises the chromosomes housed in each cell’s nucleus encodes the recipes for how to make proteins, which are responsible for the majority of the physiological actions that sustain life. Individual recipes are transcribed using messenger RNA, which carries this piece of code to a piece of cellular machinery called the ribosome. The ribosome translates the message into amino acids—the building blocks of proteins.
But sometimes messages get garbled. The resulting incomplete